Patient-reported outcomes (PROs) from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) in patients (pts) with HER2-low metastatic breast cancer (MBC)

N.T. Ueno; W. Jacot; T. Yamashita; J. Sohn; E. Tokunaga; A. Prat; J. Tsurutani; Y.H. Park; H.S. Rugo; B. Xu; F. Cardoso; Z. Mitri; R. Mahtani; K. Dunton; Y. Wang; D. Gambhire; F. Cottone; N. Harbeck; D.A. Cameron; S. Modi

doi:10.1016/j.annonc.2022.07.256

YUHSpace

BROWSE

0 159

Cited 0 times in

Patient-reported outcomes (PROs) from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) in patients (pts) with HER2-low metastatic breast cancer (MBC)

Authors: N.T. Ueno ; W. Jacot ; T. Yamashita ; J. Sohn ; E. Tokunaga ; A. Prat ; J. Tsurutani ; Y.H. Park ; H.S. Rugo ; B. Xu ; F. Cardoso ; Z. Mitri ; R. Mahtani ; K. Dunton ; Y. Wang ; D. Gambhire ; F. Cottone ; N. Harbeck ; D.A. Cameron ; S. Modi